Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating alflutinib in advanced non-small cell lung cancer reports safety, tolerability, pharmacokinetics and anti-tumor activity; the study sta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alflutinib (alflutinib)

Snippet

Sponsor: Allist Pharmaceuticals, Inc. | Conditions: NSCLC | Phase 1 | Status: TERMINATED